RT Journal Article
SR Electronic
T1 Quantifying the dynamics of COVID-19 burden and impact of interventions in Java, Indonesia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.10.02.20198663
DO 10.1101/2020.10.02.20198663
A1 Djaafara, Bimandra A
A1 Whittaker, Charles
A1 Watson, Oliver J
A1 Verity, Robert
A1 Brazeau, Nicholas F
A1 Widyastuti, Widyastuti
A1 Oktavia, Dwi
A1 Adrian, Verry
A1 Salama, Ngabila
A1 Bhatia, Sangeeta
A1 Nouvellet, Pierre
A1 Sherrard-Smith, Ellie
A1 Churcher, Thomas S
A1 Surendra, Henry
A1 Lina, Rosa N
A1 Ekawati, Lenny L
A1 Lestari, Karina D
A1 Andrianto, Adhi
A1 Thwaites, Guy
A1 Baird, J Kevin
A1 Ghani, Azra C
A1 Elyazar, Iqbal RF
A1 Walker, Patrick GT
YR 2021
UL http://medrxiv.org/content/early/2021/02/15/2020.10.02.20198663.abstract
AB Background As in many countries, quantifying COVID-19 spread in Indonesia remains challenging due to testing limitations. In Java, non-pharmaceutical interventions (NPIs) were implemented throughout 2020. However, as a vaccination campaign launches, cases and deaths are rising across the island.Methods We used modelling to explore the extent to which data on burials in Jakarta using strict COVID-19 protocols (C19P) provide additional insight into the transmissibility of the disease, epidemic trajectory, and the impact of NPIs. We assess how implementation of NPIs in early 2021 will shape the epidemic during the period of likely vaccine roll-out.Results C19P burial data in Jakarta suggest a death toll approximately 3.3 times higher than reported. Transmission estimates using these data suggest earlier, larger, and more sustained impact of NPIs. Measures to reduce sub-national spread, particularly during Ramadan, substantially mitigated spread to more vulnerable rural areas. Given current trajectory, daily cases and deaths are likely to increase in most regions as the vaccine is rolled-out. Transmission may peak in early 2021 in Jakarta if current levels of control are maintained. However, relaxation of control measures is likely to lead to a subsequent resurgence in the absence of an effective vaccination campaign.Conclusion Syndromic measures of mortality provide a more complete picture of COVID-19 severity upon which to base decision-making. The high potential impact of the vaccine in Java is attributable to reductions in transmission to date and dependent on these being maintained. Increases in control in the relatively short-term will likely yield large, synergistic increases in vaccine impact.What is already known?In many settings, limited SARS-CoV-2 testing makes it difficult to estimate the true trajectory and associated burden of the virus.Non-pharmaceutical interventions (NPIs) are key tools to mitigate SARS-CoV-2 transmission.Vaccines show promise but effectiveness depends upon prioritization strategies, roll-out and uptake.What are the new findings?This study gives evidence of the value of syndrome-based mortality as a metric, which is less dependent upon testing capacity with which to estimate transmission trends and evaluate intervention impact.NPIs implemented in Java earlier in the pandemic have substantially slowed the course of the epidemic with movement restrictions during Ramadan preventing spread to more vulnerable rural populations.Population-level immunity remains below proposed herd-immunity thresholds for the virus, though it is likely substantially higher in Jakarta.What do the new findings imply?Given current levels of control, upwards trends in deaths are likely to continue in many provinces while the vaccine is scheduled to be rolled out. A key exception is Jakarta where population-level immunity may increase to a level where the epidemic begins to decline before the vaccine campaign has reached high coverage.Further relaxation of measures would lead to more rapidly progressing epidemics, depleting the eventual incremental effectiveness of the vaccine. Maintaining adherence to control measures in Jakarta may be particularly challenging if the epidemic enters a decline phase but will remain necessary to prevent a subsequent large wave. Elsewhere, higher levels of control with NPIs are likely to yield high synergistic vaccine impact.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Centre funding from the UK Medical Research Council under a concordat with the UK Foreign, Commonwealth and Development Office and the Wellcome Trust, also under a concordat with the UK Foreign, Commonwealth and Development Office. BAD acknowledges a matched MRC Centre 1+3 studentship funding by Imperial College London School of Public Health. IRFE acknowledges a funding from Oxford University Clinical Reseach Unit (OUCRU) Strategic Committee Research for COVID-19, Vietnam. JKB, IRFE, LLE, KDL, RNL, AA, HS are supported by the Wellcome Trust, UK (106680/Z/14/Z). GT is supported by the Wellcome Trust, UK (110179/Z/15/Z). CW acknowledges funding from a UK Medical Research Council Doctoral Training Partnership (DTP) studentship.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No approvals necessaryAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData used are publicly available from these websites: 1. https://corona.jakarta.go.id/id/data-pemantauan 2. https://covid19.go.id/peta-sebaran 3. http://kcov.id/daftarpositif 4. https://www.who.int/indonesia/news/novel-coronavirus/situation-reports